Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has issued an update.

It’s been an eventful year for Texas hook and bullet crowds. Among other things, we saw the opening of the first new major ...

The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines.

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

The European Commission has granted orphan drug status to mitapivat, an oral investigational therapy for sickle cell disease.

Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...

A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...

BeiGene (BGNE) announced the FDA has approved TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, for the ...

Elon Musk has revealed he has upgraded from Ozempic to Mounjaro, nicknamed the “King Kong” of weight-loss drugs, in a photo ...